(Q53571131)

15 May 2018

title

The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines. (English)

1 reference

15 May 2018

1 reference

1 reference

Helen M Coley

1

1 reference

15 May 2018

Christine F Shotton

series ordinal

2

1 reference

15 May 2018

Maria I Kokkinos

series ordinal

3

1 reference

15 May 2018

Hilary Thomas

series ordinal

4

1 reference

15 May 2018

language of work or name

English

0 references

publication date

14 February 2007

1 reference

15 May 2018

published in

Gynecologic Oncology

1 reference

15 May 2018

volume

105

1 reference

15 May 2018

issue

2

1 reference

15 May 2018

page(s)

462-469

1 reference

15 May 2018

Systemic therapy for advanced uterine sarcoma: a systematic review of the literature

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Synergism of cisplatin and mitomycin C in sensitive and resistant cell subpopulations of a tumor model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

P16/MTS1 and pRB expression in endometrial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Anticancer drug targets: cell cycle and checkpoint control.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Inhibition of CDKs as a therapeutic modality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.004

10.1016/J.YGYNO.2007.01.004

7 January 2021

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018